Safety and Tolerability of Adoptive Cell Therapy in Cancer.

Abstract:

:Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] engineered T cells) to mediate cancer rejection. In recent years, some ACTs have produced unprecedented breakthrough responses: TIL therapy has moved from melanoma to solid tumor applications, TCR-engineered cells are developed for hematologic and solid tumors, and CAR-engineered T cells have received Food and Drug Administration (FDA) approval for the treatment of patients with certain B-cell malignancies. Although results are encouraging, to date, only a small percentage of patients with advanced malignancies can benefit from ACT. Besides ACT availability and accessibility, treatment-related toxicities represent a major hurdle in the widespread implementation of this therapeutic modality. The large variety of observed toxicities is caused by the infused cell product or as side effects of accompanying medication and chemotherapy. Toxicities can occur immediately or can be delayed. In order to render those highly promising therapeutic approaches safe enough for a wider pool of patients outside of clinical trials, an international consensus for toxicity management needs to be established.

journal_name

Drug Saf

journal_title

Drug safety

authors

Wolf B,Zimmermann S,Arber C,Irving M,Trueb L,Coukos G

doi

10.1007/s40264-018-0779-3

subject

Has Abstract

pub_date

2019-02-01 00:00:00

pages

315-334

issue

2

eissn

0114-5916

issn

1179-1942

pii

10.1007/s40264-018-0779-3

journal_volume

42

pub_type

杂志文章,评审
  • Enabling Data-Driven Clinical Quality Assurance: Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning.

    abstract:INTRODUCTION:Adverse event (AE) under-reporting has been a recurrent issue raised during health authorities Good Clinical Practices (GCP) inspections and audits. Moreover, safety under-reporting poses a risk to patient safety and data integrity. The current clinical Quality Assurance (QA) practices used to detect AE un...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00831-4

    authors: Ménard T,Barmaz Y,Koneswarakantha B,Bowling R,Popko L

    更新日期:2019-09-01 00:00:00

  • Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis.

    abstract::Phytoestrogens, plant chemicals classified as isoflavones, coumestans and lignans, display estrogen-like activity because of their structural similarity to human estrogens and exhibit high affinity binding for the estrogen receptor beta. They are common components of food items such as grains, beans, fruits and nuts. ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200124090-00003

    authors: Sirtori CR

    更新日期:2001-01-01 00:00:00

  • Treating breast cancer during pregnancy. What can be taken safely?

    abstract::The occurrence of breast cancer during pregnancy is a rare clinical situation. However, if it is diagnosed, a multidisciplinary approach involving an obstetrician, a medical oncologist and a surgeon is needed. In this situation, breast cancer should be treated according to the same principles applied in nonpregnant pa...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199818020-00005

    authors: Espié M,Cuvier C

    更新日期:1998-02-01 00:00:00

  • A benefit-risk assessment of misoprostol for cervical ripening and labour induction.

    abstract::Misoprostol, a prostaglandin E(1) analogue, is widely used in the US and other countries for cervical ripening and labour induction. Its use for these indications is not approved by the US Food and Drug Administration (FDA). The manufacturer of misoprostol issued a letter to American healthcare providers in August 200...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225090-00005

    authors: Wing DA

    更新日期:2002-01-01 00:00:00

  • Managing Risks with Immune Therapies in Multiple Sclerosis.

    abstract::Since the introduction of the interferons in the 1990s, a multitude of different immunomodulatory and immunosuppressant disease-modifying therapies for multiple sclerosis (MS) have been developed. They have all shown positive effects on clinical endpoints such as relapse rate and disease progression and are a heteroge...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0782-8

    authors: Förster M,Küry P,Aktas O,Warnke C,Havla J,Hohlfeld R,Mares J,Hartung HP,Kremer D

    更新日期:2019-05-01 00:00:00

  • Discontinuation of beta-blockers and the risk of myocardial infarction in the elderly.

    abstract:BACKGROUND:It has been shown that the abrupt cessation of treatment with beta-adrenoceptor antagonists (beta-blockers) increases the risk of myocardial infarction in patients with hypertension. As beta-blockers differ in their pharmacokinetic and pharmacodynamic properties, this risk of discontinuation might also diffe...

    journal_title:Drug safety

    pub_type: 临床试验,杂志文章

    doi:10.2165/00002018-200730060-00008

    authors: Teichert M,de Smet PA,Hofman A,Witteman JC,Stricker BH

    更新日期:2007-01-01 00:00:00

  • An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centre.

    abstract:BACKGROUND:Academic medical centres face the need to care for patients with complex medical conditions, educate physicians-in-training and conduct research, all with increasingly constrained budgets. The adoption of new therapeutic technology presents challenges and opportunities in each of these areas. Severe sepsis r...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200427150-00008

    authors: Fischer MA,Lilly CM,Churchill WW,Baden LR,Avorn J

    更新日期:2004-01-01 00:00:00

  • Age at First Rotavirus Vaccination and Risk of Intussusception in Infants: A Public Health Modeling Analysis.

    abstract:INTRODUCTION:The epidemiology of naturally occurring intussusception is known to increase significantly between the ages of 3 and 8 months. Post-licensure studies have reported a fivefold and twofold increase in intussusception in the first week after the first dose and second dose, respectively, of current rotavirus v...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-016-0424-y

    authors: Yung CF,Chong CY,Thoon KC

    更新日期:2016-08-01 00:00:00

  • The clinical significance of antibiotic-associated pseudomembranous colitis in the 1990s.

    abstract::Antibiotic-associated pseudomembranous colitis is an uncommon but potentially serious adverse reaction, resulting in acute diarrhoea and characterised by colonic pseudomembranes. A direct relationship between the disease, recent antibiotic therapy and proliferation of Clostridium difficile in the colonic lumen was est...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199106050-00004

    authors: Andréjak M,Schmit JL,Tondriaux A

    更新日期:1991-09-01 00:00:00

  • Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data.

    abstract:OBJECTIVE:Minocycline is an antibacterial drug used in the treatment of acne. Concern has been expressed over the possibility of severe adverse reactions to minocycline, including hepatitis. This study set out to identify and characterise reported cases of hepatotoxicity associated with the use of minocycline. METHODS...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200023040-00006

    authors: Lawrenson RA,Seaman HE,Sundström A,Williams TJ,Farmer RD

    更新日期:2000-10-01 00:00:00

  • The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.

    abstract::All national guidelines for the management of hypertension recommend angiotensin receptor blockers (ARBs) as an initial or add-on antihypertensive therapy. The eight available ARBs have variable clinical efficacy when used for control of hypertension. Additive blood pressure-lowering effects have been demonstrated whe...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-014-0239-7

    authors: Abraham HM,White CM,White WB

    更新日期:2015-01-01 00:00:00

  • Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting.

    abstract:INTRODUCTION:The use of mobile apps is increasing in medicine. In pharmacovigilance, mobile apps may help to increase adverse drug reaction reporting and improve the communication of safety issues. The Toulouse University Pharmacovigilance Center has developed VigiBIP®, a free smartphone app available on Android and Ap...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-017-0630-2

    authors: Montastruc F,Bagheri H,Lacroix I,Damase-Michel C,Chebane L,Rousseau V,Jouanjus E,Lapeyre-Mestre M,Durrieu G,Montastruc JL

    更新日期:2018-05-01 00:00:00

  • Management options for cancer therapy-related anaemia.

    abstract::Anaemia is common in patients with haematological malignancy, occurring in the majority of patients with malignant disease who are treated with chemotherapy. Most patients will have their anaemia attributed to the cytokine-mediated anaemia of chronic disease. Many of these patients with anaemia will be symptomatic wit...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225070-00006

    authors: Littlewood TJ

    更新日期:2002-01-01 00:00:00

  • Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.

    abstract:BACKGROUND:Although systems to collect information about suspected adverse drug reactions (ADRs) were established in many countries and by the WHO in the 1960s, few studies have examined reported ADRs related to national income. OBJECTIVE:The aim of the study was to characterize ADRs reported to the WHO-ADR database, ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03262002

    authors: Aagaard L,Strandell J,Melskens L,Petersen PS,Holme Hansen E

    更新日期:2012-12-01 00:00:00

  • Reports of sexual disorders related to serotonin reuptake inhibitors in the French pharmacovigilance database: an example of underreporting.

    abstract:BACKGROUND:Depressive disorders and use of antidepressants are associated with adverse effects on sexual function. In pharmacoepidemiological studies, sexual disorders are reported by more than 50 % of patients taking serotonin reuptake inhibitors (SRIs). OBJECTIVE:The aim of this study was to determine the reporting ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0069-z

    authors: Trenque T,Maura G,Herlem E,Vallet C,Sole E,Auriche P,Drame M

    更新日期:2013-07-01 00:00:00

  • Intentional rechallenge: does the benefit outweigh the risk?

    abstract::Rechallenge is defined as the readministration of a medication suspected of being a possible cause of an adverse reaction and which has been discontinued as result. It may be unintentional when the appearance of a reaction was initially not attributed to the medication. A rechallenge may be intentional when a prescrib...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0020-3

    authors: Stanulović V,Venegoni M,Edwards B

    更新日期:2013-03-01 00:00:00

  • Antihyperlipidaemic agents. Drug interactions of clinical significance.

    abstract::The available antihyperlipidaemic drugs are generally safe and effective, and major systemic adverse effects are uncommon. However, because of their complex mechanisms of action, careful monitoring is required to identify and correct potential drug interactions. Bile acid sequestrants are the most difficult of these a...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199411050-00002

    authors: Farmer JA,Gotto AM Jr

    更新日期:1994-11-01 00:00:00

  • Cardiac effects of ebastine and other antihistamines in humans.

    abstract::The electrocardiographic effects of ebastine and its active metabolite, carebastine, have been studied alone and in relevant drug-interaction studies in various patient populations. The overall cardiac tolerability of ebastine is excellent. In ebastine dose-ranging studies in adults and children, there were no meaning...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199921001-00009

    authors: Moss AJ,Morganroth J

    更新日期:1999-01-01 00:00:00

  • Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.

    abstract:OBJECTIVES:A prescription event monitoring (PEM) postmarketing surveillance study was carried out to examine the safety of zafirlukast as used in general practice in England. METHODS:Exposure data were obtained from the first National Health Service (NHS) prescription dispensed for patients whose prescription details ...

    journal_title:Drug safety

    pub_type: 临床试验,杂志文章

    doi:10.2165/00002018-200730050-00005

    authors: Twaites BR,Wilton LV,Shakir SA

    更新日期:2007-01-01 00:00:00

  • Erice Call for Change: Utilising Patient Experiences to Enhance the Quality and Safety of Healthcare.

    abstract::This 'Erice Call for Change' is a report from a group of experts, patients and patient representatives who met in Erice in September 2019 following previous similar meetings after the original Erice Declaration (1996). The aim of the meeting was to discuss the challenge of causal complexity and individual variation in...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-00919-2

    authors: Rocca E,Anjum RL

    更新日期:2020-06-01 00:00:00

  • Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?

    abstract::Regular treatment with both long- and short-acting beta 2-agonists results in tolerance to their bronchoprotective effects, although the relevance of this phenomenon in terms of long term asthma control remains unclear. However, there appears to be no appreciable difference between the 2 long-active beta 2-agonists, s...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199716050-00002

    authors: Lipworth BJ

    更新日期:1997-05-01 00:00:00

  • Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers.

    abstract::Several anticancer drugs have been associated with cardiac toxicity, especially the anthracyclines and trastuzumab. The pathogenesis of anthracycline-associated toxicity has been well described, whereas the mechanism of trastuzumab-associated toxicity is unknown. Although routine cardiac imaging studies (e.g. echocard...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225050-00001

    authors: Sparano JA,Brown DL,Wolff AC

    更新日期:2002-01-01 00:00:00

  • Clinical features and management of severe dermatological reactions to drugs.

    abstract::Cutaneous adverse drug reactions are a frequent occurrence and have been reported in more than 2% of hospitalised patients. Among the most commonly involved drugs are sulphonamides, penicillins, anticonvulsants and non-steroidal anti-inflammatory drugs. Two groups of mechanisms are involved in the pathogenesis of drug...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199005010-00005

    authors: Raviglione MC,Pablos-Mendez A,Battan R

    更新日期:1990-01-01 00:00:00

  • Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.

    abstract:BACKGROUND:Several efforts are under way to develop and test methods for prospective drug safety monitoring using large, electronic claims databases. Prospective monitoring systems must incorporate signalling algorithms and techniques to mitigate confounding in order to minimize false positive and false negative signal...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11594770-000000000-00000

    authors: Wahl PM,Gagne JJ,Wasser TE,Eisenberg DF,Rodgers JK,Daniel GW,Wilson M,Schneeweiss S,Rassen JA,Patrick AR,Avorn J,Bohn RL

    更新日期:2012-05-01 00:00:00

  • Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.

    abstract:BACKGROUND:Examination of clinical data routinely recorded in general practice provides significant opportunities for identifying and quantifying medicine-related adverse events not captured by spontaneous adverse reaction reporting systems. Robust pharmacovigilance methods for detecting and monitoring adverse events d...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03261970

    authors: Tomlin A,Reith D,Dovey S,Tilyard M

    更新日期:2012-09-01 00:00:00

  • Safety of inhaled and intranasal corticosteroids: lessons for the new millennium.

    abstract::Although inhaled and intranasal corticosteroids are first-line therapy for asthma and allergic rhinitis, there has recently been an increasing awareness of their propensity to produce systemic adverse effects. The availability of more potent and lipophilic corticosteroids and new chlorofluorocarbon (CFC)-free formulat...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200023010-00002

    authors: Lipworth BJ,Jackson CM

    更新日期:2000-07-01 00:00:00

  • Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data.

    abstract::Randomized controlled trials always report the dose assessed and usually include a measure of adherence. By comparison, observational studies assessing medication safety often fail to report the dose used and rarely report any measure of adherence to therapy. This limits the ability to control for differences in doses...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-015-0347-z

    authors: Roughead EE,Pratt NL

    更新日期:2015-12-01 00:00:00

  • Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease.

    abstract::Probiotics have seen widespread use for a variety of gastrointestinal problems, especially in two common disorders: irritable bowel syndrome and inflammatory bowel disease. Since a wide variety of probiotic preparations has been used, and despite a large number of studies performed, a great deal of heterogeneity exist...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-015-0349-x

    authors: Bennett WE Jr

    更新日期:2016-04-01 00:00:00

  • Safety and tolerability of the antibacterial rifaximin in the treatment of travellers' diarrhoea.

    abstract::Although travellers' diarrhoea can sometimes be associated with postinfectious complications, the condition is typically self-limiting. The infectious-diarrhoea guidelines subcommittees of the Infectious Disease Society of America and the American College of Gastroenterology recommend empirical antibacterial therapy f...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629030-00004

    authors: Ericsson CD

    更新日期:2006-01-01 00:00:00

  • Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety.

    abstract:BACKGROUND:Naproxen, ibuprofen and diclofenac are frequently used as comparators in randomized controlled trials (RCTs) on the safety and efficacy of cyclooxygenase (COX)-2 inhibitors. Different comparator doses may influence the results of RCTs. It has been hypothesized that RCTs of COX-2 inhibitors where different do...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11590470-000000000-00000

    authors: Stefansdottir G,De Bruin ML,Knol MJ,Grobbee DE,Leufkens HG

    更新日期:2011-09-01 00:00:00